Cipla, on Thursday, signed an agreement with U.S.-based speciality pharmaceutical company Salix Pharmaceuticals Inc., granting it exclusive rights under some patent applications in the ‘Rifaximin Complexes’ patent family, which is controlled by Cipla.
In a statement, Cipla said the grant is on a world-wide basis excluding Asia (other than Japan) and Africa. Salix is required to make an up-front payment and upon achievement, additional regulatory milestone payments to Cipla in respect of the new licence agreement regarding ‘Rifaximin Complexes’ patent rights. Salix will also pay a royalty on net sales of products covered by the ‘Rifaximin Complexes’ patents licensed to Salix. Cipla last year had announced the expansion of its existing collaboration with MEDA by granting global commercialisation rights for a proprietary combination nasal spray product, Dymista. “As we look to go-live with our own front end presence in North Amercia, we are happy that through this association, we can demonstrate to the wider industry that we are open to global partnerships for the development and commercialisation of complex products,’’ Subhanu Saxena, Managing Director and Global CEO, Cipla, said in a statement.
